Results 231 to 240 of about 176,622 (333)

Cardiotoxicity related to intrapericardial infusion of bevacizumab in the treatment of lung cancer-mediated malignant pericardial effusion: a case report. [PDF]

Front Pharmacol
Wu S, Lu Y, Xu C, Liu H.
europepmc   +1 more source

Pleural Diseases: Saline Irrigation in Pleural Infection, Epidemiology of Pneumothorax, and Bevacizumab in Mesothelioma

, 2017
John Corcoran, Rob Hallifax, Ioannis Psallidas, Najib M. Rahman   +3 more
openalex   +2 more sources

High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases

The FEBS Journal, EarlyView.
High serum cholesterol is linked to colorectal cancer liver metastases (CRCLM) subtypes with poor survival (replacement pattern). Levels of cholesterol under 4 mmol·L−1 correlated with better survival and a desmoplastic pattern subtype. Furthermore, in vivo PCSK9 inhibitor evolocumab, which lowers cholesterol, reduced liver metastases.
Amatzia Gantz, Audrey Kapelanski‐Lamoureux, Miran Rada, Lucyna Krzywon, Migmar Tsamchoe, Anastasia Tsatoumas, Stephanie K. Petrillo, Nabil G. Seidah, Anthoula Lazaris, Peter Metrakos   +9 more
wiley   +1 more source

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT. [PDF]

Liver Int
Ueshima K, Tsuchiya K, Yamashita T, Shimose S, Numata K, Kodama Y, Itoh S, Tanaka Y, Kuroda H, Ohkawa K, Kuzuya T, Ikeda M, Kooka Y, Aikata H, Hiraoka A, Moriguchi M, Tateishi R, Ogasawara S, Yamamoto K, Kudo M.   +19 more
europepmc   +1 more source

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis

Hepatology Research, EarlyView.
ABSTRACT Background Hepatocellular carcinoma (HCC) with Vp4 portal vein tumor thrombosis (PVTT) has an extremely poor prognosis, and evidence for effective systemic therapy is limited. Preclinical studies suggest that hypofractionated radiation therapy (HFRT) may enhance immune checkpoint inhibitor (ICI) efficacy through immunogenic cell death and ...
Masahiko Tameda, Hideaki Tanaka, Yutaka Toyomasu, Mizuki Kawachi, Hirono Owa, Mone Tsukimoto, Yasuyuki Tamai, Naoto Fujiwara, Ryuta Shigefuku, Suguru Ogura, Yoshihito Nomoto, Hayato Nakagawa   +11 more
wiley   +1 more source

Transcriptomic analysis identifies a potential target for bevacizumab resistant glioblastoma. [PDF]

Sci Rep
Lodha R, Muller-Greven G, Maqbool MA, Guo L, Buchan G, Singh K, Qadan MA, Chelakkot VS, Decker PA, Bakken K, Carlson BL, Burgenske D, Nowacki AS, Vasmatzis G, Kizilbash SH, Sarkaria JN, Gladson CL.   +16 more
europepmc   +1 more source

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources

Clinical case use bevacizumab for patient with metastatic ovarian cancer

, 2014
M. R. Oganyan, О. В. Давиденко   +1 more
openalex   +2 more sources

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

Hepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Mizuki Ariga, Sayaka Morisaki, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka   +13 more
wiley   +1 more source

Chemotherapy-free combination strategies in recurrent platinum-resistant ovarian cancer: promise, evidence and perspectives. [PDF]

Transl Cancer Res
Corbaux P, Freyer G.
europepmc   +1 more source